Search results (42)
« Back to NewsIt’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard
13 September 2022
A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees
Novel all-in-one vaccine developed to tackle future coronavirus threats
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
Oxford scientist named Australian of the Year in the UK
9 May 2022
Awards & Appointments COVID-19 Public Engagement Vaccinology
The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.
Oxford to work with Brazil to establish clinical research hub
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
Oxford vaccine reaches one billion doses released
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
Oxford Vaccine Group among winners at NHS Parliamentary awards
9 July 2021
Awards & Appointments COVID-19 Vaccinology
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
COVID-19 Clinical Trials Vaccinology
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
COVID-19 Clinical Trials Vaccinology
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
First trial participants vaccinated with Oxford COVID-19 variant vaccine
28 June 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study
21 June 2021
COVID-19 Publication Vaccinology
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant
14 May 2021
For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity
13 May 2021
Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots
6 May 2021
Andrew Pollard writes about vaccine equity in his article for The Conversation.
Increasing vaccine uptake among ethnic minorities
6 May 2021
COVID-19 Public Engagement Research Vaccinology
Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
Human challenge trial launches to study immune response to COVID-19
20 April 2021
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Alternating vaccines trial expands to include two additional vaccines
14 April 2021
COVID-19 Clinical Trials Vaccinology
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
UK and EU regulators conclude benefits of vaccination continue to outweigh the risks
7 April 2021
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
Oxford University researchers release cheap, quick COVID-19 antibody test
31 March 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.